У нас вы можете посмотреть бесплатно 1st line chemotherapy in metastatic pancreatic ductal adenocarcinoma (mPDAC) или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
In this video, Prof Eileen O’Reilly discusses 1st line chemotherapy therapies for patients with metastatic pancreatic ductal adenocarcinoma (PDAC), drawing on data from key clinical trials such as PRODIGE, MPACT, NAPOLI-3 and POLO. Summary points Cytotoxic chemotherapy remains the cornerstone of systemic therapy for advanced or metastatic pancreatic cancer NALIRIFOX is a possible new option for frontline therapy based on the NAPOLI-3 clinical trial Maintenance therapy after a period of chemotherapy is an option for patients with BRCA or PALB2 alterations Treatment selection depends on several factors, including patients' performance status and co-morbidities. These should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens Treatment strategies can be implemented to manage toxicities associated with the different chemotherapy regimens to enable a patient to stay on treatment for optimal efficacy Key clinical takeaways Pancreatic ductal adenocarcinoma (PDAC) is usually diagnosed at an advanced, incurable stage due to non-specific symptoms and has an extremely poor prognosis Systemic chemotherapy is the standard treatment for metastatic PDAC but molecularly targeted treatments and immunotherapies may have a role for specific patients Treatment selection depends on several factors, including patients' performance status and co-morbidities. These should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens Treatment strategies can be implemented to manage toxicities associated with the different chemotherapy regimens to enable a patient to stay on treatment for optimal efficacy Download the accompanying slides at https://cor2ed.com/gi-connect/program... Follow us on social media: LinkedIn: / giconnect X: https://x.com/giconnectInfo This content is intended for healthcare professionals only. The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This video is supported by an Independent Education Grant from Ipsen USA. This video was developed by https://cor2ed.com/ Published April 2025 Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.